A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients by Yang, T-S et al.
A randomised phase II study of pegylated arginine deiminase
(ADI-PEG 20) in Asian advanced hepatocellular carcinoma
patients
T-S Yang
1,11, S-N Lu
2,11, Y Chao
3, I-S Sheen*,1, C-C Lin
1, T-E Wang
4, S-C Chen
5, J-H Wang
2, L-Y Liao
6,
JA Thomson
7, J Wang-Peng
8, P-J Chen*,9 and L-T Chen*,5,8,10
1Department of Internal Medicine, Chang Gung Memorial Hospital, LinKou Medical Center, Chang Gung University, Taoyuan 33305, Taiwan;
2Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan;
3Cancer Center, Taipei Veterans General
Hospital, Taipei 112, Taiwan;
4Department of Internal Medicine, Mackay Memorial Hospital, Taipei 10449, Taiwan;
5Department of Internal Medicine,
Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan;
6Department of Internal Medicine, Ren-Ai Branch, Taipei
City Hospital, Taipei 106, Taiwan;
7Polaris Pharmaceuticals Inc., San Diego, CA, USA;
8National Institute of Cancer Research, National Health Research
Institutes, 2F, No. 367, Sheng-Li Road, Tainan 704, Taiwan;
9Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan;
10Department of Internal Medicine, National Cheng Kung University Hospital and College of Medicine, Tainan 704, Taiwan
BACKGROUND: Human hepatocellular carcinoma (HCC) cells are largely deficient of argininosuccinate synthetase and thus auxotrophic
for arginine. This study aims to investigate the efficacy and pharmacodynamics of pegylated arginine deiminase (ADI-PEG 20),
a systemic arginine deprivation agent, in Asian HCC patients.
METHODS: Patients with advanced HCC who were not candidates for local therapy were eligible and randomly assigned to receive
weekly intramuscular injections of ADI-PEG 20 at doses of 160 or 320IUm
 2. The primary end point was disease-control rate
(DCR).
RESULTS: Of the 71 accruals, 43.6% had failed previous systemic treatment. There were no objective responders. The DCR and the
median overall survival (OS) of the intent-to-treat population were 31.0% (95% confidence interval (CI): 20.5–43.1) and 7.3 (95% CI:
4.7–9.9) months respectively. Both efficacy parameters were comparable between the two study arms. The median OS of patients
with undetectable circulating arginine for more than or equal to and o4 weeks was 10.0 (95% CI: 2.1–17.9) and 5.8 (95% CI:
1.4–10.1) months respectively (P¼0.251, log-rank test). The major treatment-related adverse events were grades 1–2 local and/or
allergic reactions.
CONCLUSIONS: ADI-PEG 20 is safe and efficacious in stabilising the progression of heavily pretreated advanced HCC in an Asian
population, and deserves further exploration.
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Hepatocellular carcinoma (HCC) is one of the most common
malignancies in the world (Ryder, 2003; Sun et al, 2003; Yu and
Keeffe, 2003; Llovet, 2005; El-Serag and Rudolph, 2007). There
are approximately 500000 new cases diagnosed annually world-
wide. The majority of them are diagnosed with advanced disease
that is not amenable to effective local therapies such as liver
transplantation, resection, percutaneous ablation or transcatheter
arterial chemoembolisation (TACE) therapy. Systemic chemo-
therapy, for instance the conventional ‘standard’ therapy of
doxorubicin, has been largely ineffective and typically associated
with many side effects (Di Maio et al, 2002; Ryder, 2003; Llovet,
2005; Chen et al, 2006). As a result, placebo has remained as an
acceptable control in randomised phase III trials until sorafenib
(Nexavar; Bayer HealthCare AG, Leverkusen, Germany) was shown
to improve the survival of advanced HCC over placebo in both
Caucasian and Asian populations (Llovet et al, 2008; Cheng et al,
2009). Despite odds ratio of 0.6–0.7 compared with placebo-
control in both studies, the absolute improvement was not more
than 2–3 months. Therefore, pursuing additional options of
effective and tolerable systemic therapies for advanced HCC is still
mandatory (O’Neill and Venook, 2007; Abou-Alfa and Venook,
2008; Zhu, 2008).
Arginine is a non-essential amino acid for humans and mice
(Rogers, 1994; Tapiero et al, 2002). It is synthesised in humans and
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sother mammals from citrulline in two steps through the urea cycle
enzymes, argininosuccinate synthetase (ASS) and arginino-
succinate lyase (ASL). ASS catalyses the conversion of citrulline
and aspartic acid to argininosuccinate, which is then converted
to arginine and fumaric acid by ASL. It has long been known that
some tumour cells are auxotrophic for arginine, based on the
observations that normal cells derived from liver, kidney and testes
could grow in medium depleted of arginine but supplemented with
citrulline, whereas tumour cells from these organs could not
(Tytell and Neuman, 1960). Other investigators reported that
certain tumour cell lines could not be maintained in medium
contaminated with Mycoplasma species, which could be attributed
to arginine depletion mediated by Mycoplasma-produced arginine
deiminase (ADI; Kenny and Pollock, 1963; Kraemer et al, 1963;
Kraemer, 1964; Sugimura et al, 1990). These observations
indicated that ADI, through depletion of circulating arginine,
might be a potential anti-cancer agent. The enzyme was cloned and
expressed in E. coli and subsequently conjugated to polyethylene
glycol (PEG) to increase the circulating half-life and decrease the
immunogenicity of the recombinant Mycoplasma enzyme (Takaku
et al, 1992, 1993; Holtsberg et al, 2002).
It has been shown that some human HCC and melanoma cell
lines and tissue samples do not express ASS, making them
auxotrophic for arginine and thus reasonable candidates for
arginine deprivation therapy (Ensor et al, 2002; Dillon et al, 2004).
The first phase I/II study of pegylated arginine deiminase
(ADI-PEG 20) for unresectable HCC was reported in 2004 (Izzo
et al, 2004). In that dose-escalating study, 160IUm
 2 was selected
as the optimal biologic dose for weekly ADI-PEG 20 therapy, as it
sustained depletion of circulating arginine for 7 days. Among the
19 enrolled patients, the best tumour response was objective
response in 47.4% (two CR, seven PR) and stable disease in 36.8%,
and the median survival was 410 days. No significant toxicity was
observed even in patients who had persistent arginine depletion
for 3 or more months. In a more recent phase II study, Glazer et al
(2010) showed that this agent could achieve 2.5% of objective
response rate and 65% of diseases control rate in 80 Caucasian
patients with predominantly hepatitis C-related HCC and minimal
prior systemic therapy. This parallel phase II study aims to
investigate the therapeutic efficacy of ADI-PEG 20 for advanced
HCC in an Asian population.
MATERIALS AND METHODS
Trial design and participants
This was an open-label, multi-centre, randomised phase II study
undertaken in Taiwan. The primary end point of the study was to
assess the therapeutic efficacy of ADI-PEG 20 in an Asian HCC
population in terms of disease-control rate (DCR), which was
defined as radiographic objective response (complete or partial
response) or stable disease for 8 or more weeks after ADI-PEG 20
treatment. The secondary end points were overall survival (OS),
progression-free survival (PFS) and pharmacodynamics para-
meters, that is, changes of circulating level of arginine and
citrulline and anti-ADI-PEG 20 antibody. The study was approved
by the ethics committee at each trial centre and by the Department
of Health, Executive Yuan, Taiwan, and all patients signed written
informed consent. The study followed the Declaration of Helsinki
Principles and Good Clinical Practice guidelines.
Eligibility
Patients with measurable, metastatic or locally advanced HCC that
had failed or were too advanced to have definitive local therapy,
that is, surgical resection, percutaneous ethanol or acetic acid
injection, TACE, radiofrequency ablation either alone or in
combination, were eligible. Patients were considered to have
unresectable HCC if their tumours were of either local therapy-
failed Barcelona Criteria for Liver Cancer stage B or BLCL
stage C (the presence of either major vascular invasion or distant
metastases, or in combination). The diagnosis of HCC had to have
been established by cytology or histopathology. Patients were also
required to be age of X18 years, and have an expected survival of
X12 weeks, Karnofsky performance score X80, Child–Pugh score
p8, serum levels of total bilirubin o2.0mg per 100ml, albumin
42.5g per 100ml, AST/ALT and alkaline phosphatase o5 upper
limit of normal (ULN), ammonia o70mg per 100ml, glucose
460mg per 100ml, amylase o1.5 ULN, uric acid p8mg per
100ml (with or without medication control), peripheral blood
absolute neutrophil count X1500 per ml and platelets X50000 per ml.
Female patients of childbearing age and male patients had to use
appropriate contraception during the study period. A serum HCG
pregnancy test had to be negative before entry. Previous
chemotherapy and/or targeted therapy were allowed, but had to
be 4 weeks or more (6 weeks for nitrosoureas or mitomycin C)
before entering the study, and patients were to be completely
recovered from adverse events. Other exclusion criteria included
the presence of uncontrolled inter-current illness and a history of
other malignancies within 5 years of study entry.
Therapy and clinical assessments
Enrolled patients would be randomly assigned to receive
intramuscular injection of ADI-PEG 20 (Polaris Pharmaceuticals
Inc., San Diego, CA, USA) at 160 or 320IUm
 2 on days 1, 8, 15 and
22 every 4 weeks (as one cycle). Medical history and physical
examination, serum a-fetoprotein and uric acid levels, and
circulating arginine and citrulline levels were assessed before each
ADI-PEG 20 administration. Complete blood count, blood
biochemistry tests, coagulation test, urinary analyses and anti-
ADI-PEG 20 antibody titre were assessed after every cycle
(4 weeks) of treatment. Circulating arginine and citrulline levels
were determined by mass spectrometry assays, and the plasma
anti-ADI-PEG 20 antibody level was assessed by the ELISA-based
immunogenicity assay. These pharmacodynamic parameter deter-
minations were performed in outsourced central laboratories.
Grading of adverse events and assessment of tumour response
were performed based on the National Cancer Institute Common
Toxicity Criteria, Version 3.0 and the RECIST criteria respectively
(Therasse et al, 2002). All the treatments were given until a
maximum six cycles (24 weeks) of treatment were reached unless
unacceptable toxicity, the refusal of patient, withdrawal of
informed consent or death was observed. Those who remained
progression free after six cycles of treatment could continue the
therapy in an expanded, compassionate use programme.
Statistical considerations
The primary end point of the study was DCR, which was defined as
the ratio of patients with objective tumour response (complete
or partial response) or stable disease for X8 weeks in either
dosing arm. Secondary end points were OS, PFS and changes in
pharmacodynamic parameters. According to Simon’s optimal two-
stage design for uninterested and interested ORR of 10 and 30%,
respectively, with both a and b errors probabilities of 0.05 and
0.20, respectively, 10 patients would be accrued in the first stage of
each dosing cohort (Simon, 1989). If o2 responders were observed
among the initial 10 evaluable patients in either dosing cohort,
then the dosing would be considered as ineffective and the accrual
in that cohort would be terminated. If X2 responders were
observed among the initial 10 evaluable patients in any dosing
cohort, an additional 19 patients would be accrued into the second
stage of study. If X6 responses were observed in any dosing
cohort, ADI-PEG 20 would be considered effective; otherwise, it
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swould be concluded that ADI-PEG 20 was not effective enough for
further exploration in advanced HCC. All patients who received
any assigned treatment were included in the intent-to-treat (ITT)
population. The definition of an event for OS was death from
any cause. The survival distributions were estimated using the
Kaplan–Meier method (Kaplan and Meier, 1958). w
2-Test and
Fisher’s exact test were used for descriptive variables, and
Wilcoxon Mann–Whitney approach was used for continuous
variables. Any P-values o0.05 (two-sided test) were considered
statistically significant.
RESULTS
Recruitment and demography of participants
Between October 2006 and March 2008, 71 patients from eight
participating hospitals were enrolled into the study; 37 patients
were allocated to the 160IUm
 2 dosing arm and 34 to the
320IUm
 2 dosing arm. There were 59 men (83.1%) and 12 women
(16.9%), with a median age of 55 years (range 27–82) and hepatitis
B surface antigen seropositive in 49 (69.0%). A total of 63 patients
(88.7%) had failed previous therapies, including surgery in 29
(40.8%), one or more sessions of chemoembolisation in 46
(64.8%), previous chemotherapy/targeted therapy in 31 (43.6%)
and radiation therapy in 19 (26.8%). Demographics of the patients
were well balanced except that significantly more patients in the
320IUm
 2 arm had gross vascular invasion in radiography (70.6
vs 40.5% in 160IUm
 2 arm; P¼0.017, w
2-test), as listed in Table 1.
Toxicity profiles and off-study causes
A total of 205.5 cycles were administered (median, 2.25 cycles;
range 0.5–6). At the end of the study, three (8.8%) and five
(13.5%) subjects in the 320 and 160IUm
 2 arms, respectively,
remained in the study and received the maximum of six cycles. The
most common treatment-related adverse events were of grade
1–2 and associated with systemic and local allergic reaction and
drug-related metabolic changes, that is, hypersensitivity/skin
rash in 26.8%, local tissue reaction at injection site in 22.5%,
hyperuricemia in 19.7%, pruritus in 15.5%, fatigue in 9.8%,
hyperammonemia in 4.2%, fever in 7.0% and diarrhoea in 5.6%, as
listed in Table 2. Thirteen patients (18.3%) died during the study
or within 1 month after their last treatment. These deaths were
attributed to disease progression in 11, hepatic decompensation in
1 and oesophageal varices haemorrhage in another. The clinical
characteristics of these 13 patients, at study entry, did not differ
from those of the rest of 58 patients who remained alive for more
than 1 month after last treatment.
Pharmacodynamics and immunogenicity
For both dosing cohorts, the circulating arginine level markedly
decreased after the first dose (undetectable in majority of patients
on day 8) and then rose gradually with extended time of treatment,
which was accompanied by a reciprocal change in circulating
citrulline levels, as shown in Figure 1A and B. The circulating
arginine level remained at approximately p50% of the baseline
level for about 10 weeks and 6 weeks in the 320 and 160IUm
 2
cohorts, respectively. Of note, the reported arginine levels were
obtained 1 week after the administration of ADI-PEG 20 and thus
may not accurately reflect the maximal and the duration of
suppression of arginine levels attained during the week.
Antibodies directed against ADI-PEG 20 could be detected
before cycle 2 (week 5) and generally reached a plateau before cycle
5 (week 17). The return to baseline levels of circulating arginine
closely correlated with the increase in antibody titre (Figure 1C).
Table 1 Patient demographics
Parameter/dose level 320IUm
 2 160IUm
 2 Overall
Case, number 34 37 71
Gender
Male 30 (88.2%) 29 (78.4%) 59 (83.1%)
Female 4 (11.8%) 8 (21.6%) 12 (16.9%)
Age
Median 55 56 55
Range 31–82 27–80 27–82
Karnofsky performance status
100 5 (14.7%) 5 (13.5%) 10 (14.1%)
90 21 (61.2%) 28 (75.7%) 49 (69.0%)
80 8 (23.5%) 4 (10.8%) 12 (16.9%)
Child–Pugh class
A 31 (91.2%) 34 (91.9%) 65 (91.6%)
B 3 (8.8%) 3 (8.1%) 6 (8.4%)
HbsAg
Positive 25 (73.5%) 24 (64.9%) 49 (69.0%)
Negative 9 (26.5%) 13 (35.1%) 22 (31.0%)
Anti-HCV antibody
Positive 8 (23.5%) 11 (29.7%) 19 (26.8%)
Negative 24 (76.5%) 25 (67.6%) 51 (71.8%)
Unknown 0 (0.0%) 1 (2.7%) 1 (1.4%)
Vascular invasion
Absent 10 (29.4%) 22 (59.5%) 32 (45.1%)
Present 24 (70.6%) 15 (40.5%) 39 (54.9%)
Extrahepatic metastases
Absent 15 (44.1%) 15 (40.5%) 30 (42.3%)
Present 19 (55.9%) 22 (59.5%) 41 (57.7%)
Prior therapy
Hepatic resection 11 (32.4%) 18 (48.6%) 29 (40.8%)
Transcatheter arterial
chemoembolization
21 (61.8%) 25 (67.6%) 46 (64.8%)
Radiotherapy 8 (23.5%) 11 (29.7%) 19 (26.8%)
Systemic therapy 16 (47.0%) 15 (40.5%) 31 (43.6%)
Thalidomide alone 4 (11.8%) 3 (8.1%) 7 (9.9%)
Chemotherapy with/without
thalidomide
8 (23.5%) 8 (21.6%) 16 (22.5%)
Anti-angiogenic therapy
a 4 (11.8%) 4 (10.8%) 8 (11.3%)
Abbreviation: HbsAg¼hepatitis B surface antigen.
aIncluding PI88 in 3, sorafenib in 2,
sunitinib in 1 and bevacizumab in 2.
Table 2 Treatment-related adverse events
320IUm
 2
(N¼34)
160IUm
 2
(N¼37)
Overall
(N¼71)
Adverse event
Grade
1–2
Grade
3–4
Grade
1–2
Grade
3–4
Grade
1–2
Grade
3–4
Anaemia (%) 5.9 2.7 2.7 4.2 1.4
Hypersensitivity/rash (%) 20.6 32.4 26.8
Pruritus (%) 17.6 13.5 15.5
Local reaction (%) 26.7 18.9 22.5
Fatigue (%) 5.9 2.9 10.8 8.4 1.4
Fever (%) 8.8 5.4 7.0
Diarrhea (%) 8.8 2.7 5.6
Hyperuricemia (%) 11.8 5.9 16.2 5.4 14.1 5.6
Hyperammonemia (%) 5.9 2.7 4.2
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sResponse and survival
There were no objective (complete or partial) tumour responders.
The best tumour response was stable disease in 22 patients
(31.0%), progressive disease in 43 (60.6%) and unevaluable in
6 (8.4%). The DCR (complete/partial responseþstable disease)
for the ITT populations was 31.0% (22 of 71, 95% confidence
interval (CI): 20.5–43.1). Each dose cohort had 11 patients
with stable disease as their best response. Among the 22 patients
who showed stable disease at the end of cycle 2, six (27.3%)
remained progression free at the time of last assessment.
As limited objective tumour response is commonly observed
in most targeted agent trials, we also assessed the therapeutic
efficacy of ADI-PEG 20 by monitoring changes of the serum
AFP levels. To avoid the influence of non-tumour-originating
AFP fluctuations (ie, those associated with hepatitis activity),
we only assessed AFP response in patients with baseline AFP
levels above 200ngml
 1 (Liaw et al, 1986; Chen et al, 2009) and
received treatments for at least 8 weeks. Of these 27 patients, the
changes in AFP level after 8 weeks of ADI-PEG 20 treatment were
X50% reduction in 3 (11.1%), o50% reduction in 2 (4.7%), less
than onefold increase in 9 (33.3%), one- to twofold increase in
7 (25.9%) and more than twofold increase in 6 (22.2%), as shown
in Figure 2.
The median duration of disease control was 2.8 months for both
dose cohorts, with the 95% CI of 1.4–4.3 months in 160IUm
 2
cohort and 2.4–3.3 months in 320IUm
 2 cohort. The median PFS
and OS of the ITT population were 1.8 (95% CI: 1.8–3.0) months
and 7.3 (95% CI: 4.7–9.9) months respectively. There was no
statistical difference for both PFS and OS between the two study
cohorts, with P-values 0.73 and 0.76 (log-rank test) respectively, as
listed in Table 3. The survival curves of the two dose cohorts are
plotted in Figure 3A and B.
The median survival of patients with baseline AFP level of o10
2
(N¼26), 10
2 to o10
3 (N¼12), 10
3 to o10
4 (N¼14) and 410
4
(N¼19) ngml
 1 was 11.8 (95% CI: 3.3–20.3) months, 15.7 (95%
CI: 7.6–23.8) months, 4.3 (95% CI: 0–8.8) months and 4.1 (95%
CI: 3.0–5.2) months, respectively (P¼0.0006, log-rank test).
The proposed mechanism of action of ADI-PEG 20 treatment is
the preferential starvation of tumour cells by arginine depletion, so
the correlation between the duration of arginine depletion and OS
was examined. Among the 61 subjects who had received at least
one complete cycle (four doses) of treatment, the median survival
of those with (n¼36) and without (n¼25) sustained depletion of
plasma arginine level for 4 weeks was 10.0 (95% CI: 2.1–17.9)
months and 5.8 (95% CI: 1.4–10.1) months respectively (P¼0.251,
log-rank test; Figure 4). Of the 36 patients showing depletion of
plasma arginine for 4 weeks, 13 patients continued to show
depletion of plasma arginine for 8 or more weeks. The median OS
of these 13 patients was 15.2 months (95% CI: 1.2–29.1).
In addition, we also explored the correlation between the
expression of ASS in tumour tissue and OS. Formalin-fixed,
paraffin-embedded archival tumour specimens from 44 patients
were subjected to immunohistochemical study using anti-ASS
monoclonal antibody (Polaris Pharmaceuticals Inc.) and visualised
by a biotinylated horse anti-mouse, streptavidin–HRP system
(Vector Labs Inc., Burlingame, CA, USA). Of them, 33 (75%) were
ASS deficient and 11 (25%) were ASS positive. The median OS of
all 44 patients was 5.9 (95% CI: 0.6–11.2) months, whereas the
median OS of patients with ASS-deficient and ASS-positive
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Figure 1 Changes of mean plasma (A) arginine and (B) citrulline levels,
and (C) plasma titres of anti-ADI antibody after weekly administration of
either 160 or 320IUm
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Table 3 Therapeutic efficacy
Items
320IUm
 2
(N¼34)
160IUm
 2
(N¼37)
Overall
(N¼71)
Best tumor response, % (95% CI)
Objective response 0 0 0
Stable disease
X8 weeks 32.4 (16.6–48.1) 29.7 (15.0–44.4) 31.0 (20.2–41.8)
X16 weeks 11.8 (0.9–22.6) 16.2 (0.4–28.1) 14.1 (0.6–22.2)
X24 weeks 5.9 (0.0–13.8) 10.8 (0.1–20.8) 8.4 (0.2–14.9)
Median PFS (95% CI),
months
1.9 (1.8–3.5) 1.8 (1.8–3.5) 1.8 (1.8–3.0)
Median OS (95% CI),
months
6.2 (2.8–9.6) 8.4 (3.6–13.1) 7.3 (4.7–9.9)
Abbreviations: OS¼overall survival; PFS¼progression-free survival.
[2]oth OS and
PFS were estimated by Kaplan–Meier analyses.
Phase II study of ADI-PEG 20 in HCC
T-S Yang et al
957
British Journal of Cancer (2010) 103(7), 954–960 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
stumours was 8.3 (95% CI: 3.4–14.0) and 3.3 (95% CI: 1.3–2.5)
months (P¼0.065, log-rank test).
DISCUSSION
In this study, we have shown that weekly intramuscular injection
of ADI-PEG 20 at doses of 160 or 320IUm
 2 could achieve a DCR
of 31.0% (95% CI: 20.5–43.1) and an OS of 7.3 (95% CI: 4.7–9.9)
months in a previously heavily treated Asian advanced HCC
population. The majority of the patients enrolled in this study
(88.7%) had failed one or more previous treatment modalities for
HCC, including systemic therapy in 43.6% patients. As compared
with the initial reports in smaller Caucasian cohorts, minimal
objective tumour response was observed in the studies of Glazer
et al (2010) and ours (Curley et al, 2003; Izzo et al, 2004). However,
the DCRs in current study and the Caucasian phase II study were
31 and 63% respectively (Glazer et al, 2010). The causes for
discrepancy remain unknown, but may be attributed to the higher
percentage of patients with previous systemic treatment in our
study (43.6 vs 1.3%) and/or a potential difference in how HBV- and
HCV-related HCC respond to the arginine deprivation therapy.
Unfortunately, Glazer et al reported their survival data as mean
survival after the diagnosis of unresectable HCC, which makes the
comparison of survival after treatment between the two studies
impossible.
However, the DCR and OS observed in our study were
comparable with that of 35% and 6.5 (95% CI: 5.6–7.6) months
for patients who received sorafenib in a phase III study in
Asia-Pacific region (Cheng et al, 2009). In comparison, 43.6% of
our patients had failed previous systemic therapy including
chemotherapy and anti-angiogenic therapy, which was not allowed
in the Asia-Pacific sorafenib trials. In addition, ADI-PEG 20
was relatively well tolerated as compared with sorafenib. The
major toxicities of ADI-PEG 20 were of grades 1–2 local and/or
allergic reactions, which were distinct from those adverse events
observed in association with cytotoxic or molecular targeted
agents. However, the impact of ADI-PEG 20 on the natural course
of advanced HCC has to be validated further by randomised phase
III trials. Furthermore, the effectiveness and non-overlapping
toxicity of ADI-PEG 20 make it a potential candidate to be
combined with other promising agent(s) for future clinical trials
in advanced HCC.
Our pharmacodynamic analysis confirmed that weekly treat-
ment with 160IUm
 2 was sufficient to deplete circulating arginine
for 7 days (Izzo et al, 2004). The 320IUm
 2 dose in this study was
chosen to investigate if a further increase in dosage would result in
an even more prolonged depletion of arginine and thus possibly
greater efficacy. Anti-ADI-PEG 20 antibody was detectable after
week 4 in some patients, and its frequency and titre increased after
repetitive administration of ADI-PEG 20, which was accompanied
by a gradual return of the circulating arginine levels in both study
arms. The median period of sustained reduction of circulating
arginine to o50% of baseline levels in the 160 and 320IUm
 2 dose
groups was approximately 6 weeks and 10 weeks respectively.
However, the DCR and OS were similar in both dose cohorts. It
should be noted that the circulating arginine levels reported in this
study were obtained 7 days after administration of the study
drug. The extent to which arginine was depleted immediately after
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Figure 3 Progression-free (A) and overall survival (B) curves according to the ADI-PEG 20 dose administered, 160IUm
 2 (blue line) and 320IUm
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(orange line), with P-values of 0.73 and 0.76 (log-rank test), respectively.
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Figure 4 Overall survival curves in patients with depletion of circulating
arginine for X4 weeks (orange line) and o4 weeks (blue line) of duration
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sadministration of the study drug and the duration of this level
of depletion is not known. It warrants further investigation.
However, based on the results of this study, weekly 160IUm
 2
should remain as the recommended dosing schedule in future
trials.
A post hoc analysis of the survival data revealed a potential
correlation between duration of arginine deprivation and survival
in this limited patient population. Patients with depletion of
circulating arginine for X4 weeks had a trend towards better
survival than those with depletion of arginine for o4 weeks. This
finding is consistent with what has been conceived for anti-
angiogenic therapy, an alternative selective starvation therapy
(Slaton et al, 1999). The return of circulating arginine levels was
preceded by the rising titre of anti-ADI-PEG 20 antibody.
Therefore, the therapeutic efficacy of ADI-PEG 20 therapy may
be further improved by modifying the antigenic epitope of ADI
and/or by combining ADI-PEG 20 with immune modulation or
cytotoxic therapy to diminish the production of anti-ADI-PEG 20
antibody. Furthermore, there was also a trend towards better
survival in patients with ASS-deficient HCC relative to those
who were ASS positive. The potential of using ASS status as a
predictive biomarker and/or selection criteria for arginine
deprivation therapy should be further investigated in a larger
patient population study.
Recent reports have reported that lowering peripheral blood
arginine can result in anti-angiogenesis by inhibition of nitric
oxide synthesis, alteration of immune cell tumour surveillance and
induction of autophagy (Gong et al, 2003; Bronte and Zanovello,
2005; Shen et al, 2006; Peranzoni et al, 2007; Bowles et al, 2008;
Kim et al, 2009; Delage et al, 2010). These can all be considered as
additional mechanisms of action of ADI-PEG 20.
In conclusion, ADI-PEG 20 is safe and efficacious in stabilising
the progression of advanced HCC in an Asian population. On the
basis of the results of this study, a multi-national phase III study
for HCC is being planned. In addition, the exceptional safety
profile and the unique mechanisms of action suggest that ADI-PEG
20 is a good candidate to be used in combination with other
molecular targeting or cytotoxic agents. The planning for
combination studies in patients with other ASS-deficient tumours
is currently underway.
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